$JAZZ Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$3.88 down -147.72% YoY
• Reported revenue of $1.24B up 10.38% YoY
• Jazz Pharmaceuticals expects total revenues in 2026 to increase compared to 2025; cost of product sales to be in line, SG&A to decrease, and R&D expenses to increase compared to 2025.